These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23487849)

  • 21. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
    Attard G; Belldegrun AS; de Bono JS
    BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
    Nishiyama T
    Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
    Takeda M; Hosaka M
    Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
    [No Abstract]   [Full Text] [Related]  

  • 24. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
    Attard G; Reid AH; Olmos D; de Bono JS
    Cancer Res; 2009 Jun; 69(12):4937-40. PubMed ID: 19509232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
    Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
    Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New therapeutic agents for castration-refractory prostate cancer.
    Patten DY; Sartor O
    Clin Genitourin Cancer; 2009 Aug; 7(2):E4-6. PubMed ID: 19692323
    [No Abstract]   [Full Text] [Related]  

  • 28. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.
    Pezaro C; Mukherji D; Tunariu N; Cassidy AM; Omlin A; Bianchini D; Seed G; Reid AH; Olmos D; de Bono JS; Attard G
    Br J Cancer; 2013 Jul; 109(2):325-31. PubMed ID: 23807167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
    Antonarakis ES; Eisenberger MA
    Nat Clin Pract Oncol; 2009 Jan; 6(1):12-3. PubMed ID: 18957947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
    Tagawa ST; Beltran H
    Asian J Androl; 2011 Nov; 13(6):785-6. PubMed ID: 21857690
    [No Abstract]   [Full Text] [Related]  

  • 31. Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
    Attard G; Reid AH; de Bono JS
    J Clin Oncol; 2010 Oct; 28(29):e560-1; author reply e562. PubMed ID: 20805462
    [No Abstract]   [Full Text] [Related]  

  • 32. Abiraterone acetate for castration resistant prostate cancer.
    Shah S; Ryan C
    Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.
    Francini E; Petrioli R; Fiaschi AI; Laera L; Roviello G
    Medicine (Baltimore); 2014 Dec; 93(27):e163. PubMed ID: 25501058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
    Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
    Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New options for the management of castration-resistant prostate cancer: a case perspective.
    Goetz D
    J Natl Compr Canc Netw; 2011 Feb; 9 Suppl 3():S13-23; quiz S24. PubMed ID: 21357663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abiraterone. Cougar Biotechnology.
    Madan RA; Arlen PM
    IDrugs; 2006 Jan; 9(1):49-55. PubMed ID: 16374734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Ang JE; Olmos D; de Bono JS
    Br J Cancer; 2009 Mar; 100(5):671-5. PubMed ID: 19223900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
    Prescrire Int; 2014 Feb; 23(146):40-1. PubMed ID: 24669383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
    Leroux F
    Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.